Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Kansas: - Wesley Medical Center — Wichita, Kansas
Phase 3 Recruiting Network
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT06724237
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Sites in Kansas: - Local Institution - 0216 — Westwood, Kansas
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 2 Recruiting Network
This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleuce…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05633615
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 2 Recruiting NIH
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in Kansas: - University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 2 Recruiting Network
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who …
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT06859424
Sites in Kansas: - University of Kansas Medical Center — Westwood, Kansas
Phase 1, Phase 2 Recruiting Academic/Other
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. T…
Sponsor: Leland Metheny
NCT ID: NCT03104491
Sites in Kansas: - The University of Kansas Cancer Center — Westwood, Kansas
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Kansas: - University of Kansas Clinical Research Center — Fairway, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
Phase 1 Recruiting Academic/Other
This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targe…
Sponsor: University of Kansas Medical Center
NCT ID: NCT06879340
Sites in Kansas: - University of Kansas Cancer Center — Westwood, Kansas
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Kansas: - HaysMed — Hays, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- The University of Kansas Cancer Center - Olathe — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
Recruiting Network
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in Kansas: - Central Care Cancer Center - Garden City — Garden City, Kansas
- Central Care Cancer Center - Great Bend — Great Bend, Kansas
- HaysMed — Hays, Kansas
- University of Kansas Cancer Center — Kansas City, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas